touch ONCOLOGY

  • Home
  • touch ONCOLOGY

touch ONCOLOGY touchONCOLOGY.com hosts the expert content from peer-reviewed, free-to-access journals – EU Oncology

This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations. The information posted on this channel is intended for use by licensed Healthcare Professionals (HCPs).

Curious about what your peers think on incorporating ADCs into the treatment of mBC? Join our educational activity where...
11/07/2025

Curious about what your peers think on incorporating ADCs into the treatment of mBC?

Join our educational activity where real-time questions within the video ensure you won't miss a beat!

Discover what other HCPs think about incorporating ADCs into the treatment of mBC. Engage in live polling integrated seamlessly into this activity.

Be part of the experience, learn together:
https://touchoncologyime.org/adcs-in-the-treatment-of-mbc/

📢 BCMA-targeting in multiple myeloma: What’s new in 2025?Join myeloma expert Prof. Philippe Moreau as he reviews the lat...
11/07/2025

📢 BCMA-targeting in multiple myeloma: What’s new in 2025?

Join myeloma expert Prof. Philippe Moreau as he reviews the latest BCMA-targeting data from COMy, ASCO and EHA 2025.

He is joined by Prof. Hermann Einsele and Dr Paola Neri to discuss how these updates could shape clinical practice and improve patient outcomes.

💡 Don’t miss this expert-led discussion on the evolving treatment landscape in multiple myeloma.

👉 Learn more: https://touchoncologyime.org/bcma-mm-comy-asco-eha-2025/

This activity is funded by an independent medical education grant from GSK.

This activity is provided by touchIME.

touchIME is an EBAC® accredited provider.







10/07/2025

Polish up your knowledge and stay current with the latest in diagnosing and treating fungal nail infections.

From AI and PCR to lasers, microwaves, and emerging topical and systemic therapies, the tools for diagnosing and treating onychomycosis are evolving.

In this expert-led update, Dr Shari Lipner explores:
🔍 Smarter diagnostics and how they are improving accuracy
💊 When and how best to use topical, oral or combination therapies
⚡ New antifungals and devices gaining ground
🛡️ How to reduce relapse with simple strategies

👉 Listen here: https://touchderma.com/podcast/diagnosing-and-treating-onychomycosis/

🚨 Round-up: Emerging Data in Breast Cancer 🚨This year’s ASCO meeting showcased pivotal clinical trials in breast cance...
09/07/2025

🚨 Round-up: Emerging Data in Breast Cancer 🚨

This year’s ASCO meeting showcased pivotal clinical trials in breast cancer, with data that may significantly influence practice – particularly in ER+ and triple-negative subtypes.

touchONCOLOGY is highlighting the most relevant and potentially practice-changing insights for HCPs.

👉 Explore the key updates here: https://touchoncology.com/learning-activities/

🎥 Explore the evolving role of ADCs in metastatic breast cancer careLooking for practical insights on how and when to us...
07/07/2025

🎥 Explore the evolving role of ADCs in metastatic breast cancer care

Looking for practical insights on how and when to use antibody–drug conjugates (ADCs) in real-world oncology practice?

Join Dr Alison Conlin and Prof. Giuseppe Curigliano as they discuss how to integrate ADCs across HR+/HER2–, HER2+ and triple-negative breast cancer, guided by the latest treatment guidelines and clinical evidence.

🌐 Available with subtitles in French, German, Spanish and Arabic, so you can learn in your language.

💡 What you’ll discover:
🔹 How to tailor treatment and sequencing by mBC subtype
🔹 Tips on biomarker testing and patient selection
🔹 Expert advice on managing ADC-related toxicities

🎯 Designed for busy community oncologists looking to stay up to date with best practice.

👉 Watch now: https://touchoncologyime.org/adcs-in-the-treatment-of-mbc/

This activity is funded by an independent medical education grant from Gilead Sciences, Inc.

The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

Curious about what your peers think on multidisciplinary management of TNBC: Integrating immunotherapies for early and m...
07/07/2025

Curious about what your peers think on multidisciplinary management of TNBC: Integrating immunotherapies for early and metastatic disease?

Join our educational activity where real-time questions within the video ensure you won't miss a beat!

Discover what other HCPs think about multidisciplinary management of TNBC. Engage in live polling integrated seamlessly into this activity.

Be part of the experience, learn together:
https://touchoncologyime.org/management-of-tnbc-with-immunotherapy

Curious about what your peers think on applying immunotherapy in clinical practice for patients with early-stage NSCLC? ...
04/07/2025

Curious about what your peers think on applying immunotherapy in clinical practice for patients with early-stage NSCLC?

Join our educational activity where real-time questions within the video ensure you won't miss a beat!

Discover what other HCPs think about immunotherapy in clinical practice for patients with early-stage NSCLC. Engage in live polling integrated seamlessly into this activity.

Be part of the experience, learn together:
https://touchoncologyime.org/touchexpert-focus-immunotherapy-early-stage-nsclc/

🧬 Emerging Cell Therapy Approaches in Relapsed/Refractory AML in Older AdultsOlder adults with relapsed or refractory ac...
04/07/2025

🧬 Emerging Cell Therapy Approaches in Relapsed/Refractory AML in Older Adults

Older adults with relapsed or refractory acute myeloid leukaemia (AML) face unique challenges, including high-risk mutations and treatment-limiting comorbidities.

This review explores how novel cell therapy strategies—such as adapted conditioning for stem cell transplantation—are offering new hope in this high-risk setting.

🔗 https://touchoncology.com/haematology/journal-articles/emerging-cell-therapy-approaches-in-relapsed-refractory-acute-myeloid-leukaemia-in-older-adults/

In case you missed it...💡 Optimize TNBC care with expert insights on immunotherapyIn this expert-led series, Prof. Sherk...
03/07/2025

In case you missed it...

💡 Optimize TNBC care with expert insights on immunotherapy

In this expert-led series, Prof. Sherko Kümmel, Prof. Rebecca Dent and Prof. Peter Schmid review the application of immunotherapy across early-stage and metastatic triple-negative breast cancer (TNBC), including guideline recommendations, the latest data and side effect management.

👩‍⚕️ What’s covered:
🔹 Where immunotherapy is positioned in ESMO and NCCN guidelines
🔹The role of biomarker testing to inform treatment selection in metastatic TNBC
🔹 Strategies to mitigate and manage immune-related toxicities
🔹 The value of coordinating multidisciplinary care

💡 “To give immunotherapy safely, we have to function well as a team.” — Prof. Peter Schmid

🎥 Don’t miss these practical insights from leading voices in breast cancer care.
👉 https://touchoncologyime.org/management-of-tnbc-with-immunotherapy

This activity is funded by an independent medical education grant from Merck Sharp & Dohme LLC.

This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

Address


Website

Alerts

Be the first to know and let us send you an email when touch ONCOLOGY posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to touch ONCOLOGY:

Shortcuts

  • Address
  • Alerts
  • Contact The Business
  • Claim ownership or report listing

  • Want your business to be the top-listed Media Company?

Share

Our Story

The information posted on this channel is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis or treatment recommendations.

touchONCOLOGY.com is an independent source of peer-reviewed content from our biannual journals – European Oncology & Haematology and Oncology & Hematology Review (US). Free to access, it is designed to support busy physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity. Concise and balanced articles authored by leading voices, are complemented by carefully curated video and podcasts.